BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 27780858)

  • 1. 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.
    Kerk SA; Finkel KA; Pearson AT; Warner KA; Zhang Z; Nör F; Wagner VP; Vargas PA; Wicha MS; Hurt EM; Hollingsworth RE; Tice DA; Nör JE
    Clin Cancer Res; 2017 May; 23(10):2516-2527. PubMed ID: 27780858
    [No Abstract]   [Full Text] [Related]  

  • 2. IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.
    Finkel KA; Warner KA; Kerk S; Bradford CR; McLean SA; Prince ME; Zhong H; Hurt EM; Hollingsworth RE; Wicha MS; Tice DA; Nör JE
    Neoplasia; 2016 May; 18(5):273-281. PubMed ID: 27237319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
    Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
    Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma.
    Muhammad N; Bhattacharya S; Steele R; Phillips N; Ray RB
    Clin Cancer Res; 2017 Jun; 23(12):3120-3128. PubMed ID: 27965308
    [No Abstract]   [Full Text] [Related]  

  • 5. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
    Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
    Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.
    Nör C; Zhang Z; Warner KA; Bernardi L; Visioli F; Helman JI; Roesler R; Nör JE
    Neoplasia; 2014 Feb; 16(2):137-46. PubMed ID: 24709421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
    Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
    Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro investigation of head and neck cancer stem cell proportions and their changes following X-ray irradiation as a function of HPV status.
    Reid P; Wilson P; Li Y; Marcu LG; Staudacher AH; Brown MP; Bezak E
    PLoS One; 2017; 12(10):e0186186. PubMed ID: 29028842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro.
    Sun Z; Hu W; Xu J; Kaufmann AM; Albers AE
    Int J Oncol; 2015 Oct; 47(4):1339-50. PubMed ID: 26323460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma.
    Kurth I; Hein L; Mäbert K; Peitzsch C; Koi L; Cojoc M; Kunz-Schughart L; Baumann M; Dubrovska A
    Oncotarget; 2015 Oct; 6(33):34494-509. PubMed ID: 26460734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification, expansion and characterization of cancer cells with stem cell properties from head and neck squamous cell carcinomas.
    Kaseb HO; Fohrer-Ting H; Lewis DW; Lagasse E; Gollin SM
    Exp Cell Res; 2016 Oct; 348(1):75-86. PubMed ID: 27619333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
    Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
    Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
    J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.
    Bourguignon LYW; Earle C; Shiina M
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma.
    Khammanivong A; Gopalakrishnan R; Dickerson EB
    Mol Cancer; 2014 Dec; 13():260. PubMed ID: 25471937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells.
    Lo WL; Yu CC; Chiou GY; Chen YW; Huang PI; Chien CS; Tseng LM; Chu PY; Lu KH; Chang KW; Kao SY; Chiou SH
    J Pathol; 2011 Mar; 223(4):482-95. PubMed ID: 21294122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma.
    Citron F; Armenia J; Franchin G; Polesel J; Talamini R; D'Andrea S; Sulfaro S; Croce CM; Klement W; Otasek D; Pastrello C; Tokar T; Jurisica I; French D; Bomben R; Vaccher E; Serraino D; Belletti B; Vecchione A; Barzan L; Baldassarre G
    Clin Cancer Res; 2017 Jul; 23(14):3769-3780. PubMed ID: 28174235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.